How India Exports Acarbose to the World

Acarbose, an alpha-glucosidase inhibitor used in the management of type 2 diabetes mellitus, has been approved in the United States under the brand name Precose. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for generic versions of acarbose tablets, indicating a competitive generic market. Notably, Roxane Laboratories, Inc. received approval for its ANDA 78-470 for Acarbose Tablets (25 mg, 50 mg, and 100 mg) on August 30, 2006.

The United States is the primary destination for Indian exports of acarbose, accounting for 65.5% of the total export value. This substantial market share underscores the importance of compliance with FDA regulations for Indian exporters. The FDA's regulatory pathway for generic drugs involves demonstrating bioequivalence to the reference listed drug, ensuring consistent quality, efficacy, and safety. As of March 2026, there are no active FDA import alerts specifically targeting acarbose, suggesting that current imports meet the agency's standards.

In the European Union, acarbose is authorized for use in the treatment of type 2 diabetes mellitus. The European Medicines Agency (EMA) oversees the approval and monitoring of medicinal products within the EU. Acarbose has been subject to periodic safety updates, with the most recent procedure (PSUSA/00000017/201803) concluded on November 29, 2018. (ema.europa.eu)

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for the authorization of medicinal products. Post-Brexit, the UK has established its own regulatory framework, though it continues to align closely with EU standards. Manufacturers exporting acarbose to the UK must ensure compliance with MHRA requirements, including adherence to Good Manufacturing Practice (GMP) standards.

Acarbose is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The WHO Model List serves as a guide for the development of national and institutional essential medicine lists. Additionally, acarbose is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality specifications across different regions.

In India, acarbose is classified under Schedule H of the Drugs and Cosmetics Rules, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines. As of March 2026, acarbose is not listed under the DPCO's price control list, allowing manufacturers to set prices based on market dynamics. For export purposes, Indian pharmaceutical companies must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with national export regulations.

The primary patent for acarbose, U.S. Patent No. 4,904,769, expired on September 6, 2009. This expiration has led to the entry of multiple generic versions into the market, increasing competition and accessibility. The absence of active patents or exclusivity periods as of March 2026 indicates a favorable environment for generic manufacturers and exporters.

In July 2025, the European Medicines Agency (EMA) adopted a positive opinion recommending an extension to the existing indication for Baqsimi (glucagon) to include treatment of severe hypoglycemia in children with diabetes mellitus from 1 year of age. (ema.europa.eu) While not directly related to acarbose, this development reflects the ongoing advancements in diabetes management therapies within the EU.

In December 2025, the UK's Food Standards Agency (FSA) implemented the Genetic Technology (Precision Breeding) Regulations 2025, allowing businesses to apply for Precision Bred Organism (PBO) food and feed marketing authorizations. (food.gov.uk) Although this regulation primarily pertains to genetically modified organisms, it signifies the UK's commitment to modernizing its regulatory framework for food and feed products, which may have indirect implications for pharmaceutical exports.

These developments highlight the dynamic nature of the regulatory landscape in key export markets, emphasizing the need for continuous monitoring and compliance by Indian exporters of acarbose.

Acarbose, an alpha-glucosidase inhibitor used in managing type 2 diabetes, is primarily produced in India and China. While India has a robust pharmaceutical manufacturing sector, it heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). Approximately 68% of India's API imports, including those for antidiabetic drugs like acarbose, originate from China. This dependency exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or environmental regulations affecting Chinese production facilities.

In recent years, China's stringent environmental policies have led to the shutdown of numerous chemical manufacturing plants, causing significant supply chain disruptions and escalating costs for APIs and KSMs. Such events underscore the vulnerability of India's pharmaceutical industry due to its reliance on Chinese raw materials. The COVID-19 pandemic further highlighted these risks, as lockdowns and export restrictions in China led to shortages and price volatility in essential drugs.

Our proprietary trade data from 2022 to 2026 indicates that the top five Indian exporters account for 91.9% of acarbose exports, with STRIDES PHARMA SCIENCE LIMITED alone contributing 65.5% ($4.4 million USD). This high supplier concentration poses a significant single-source risk; any operational or regulatory issues affecting these key players could disrupt the global supply of acarbose.

To mitigate such risks, the Indian government introduced the Production Linked Incentive (PLI) scheme aimed at bolstering domestic API and KSM production, thereby reducing dependence on imports. The PLI scheme has incentivized local manufacturers to invest in API production, enhancing self-reliance and supply chain resilience. (pharmanow.live)

Geopolitical tensions and shipping disruptions have further complicated the acarbose supply chain. Incidents in critical maritime routes, such as the Red Sea and the Strait of Hormuz, have led to delays and increased shipping costs. Additionally, escalating US-China trade tensions have resulted in tariffs and export restrictions, impacting the availability and pricing of APIs and KSMs sourced from China.

Regulatory bodies like the FDA and EMA have issued shortage alerts for various medications due to these supply chain challenges. While specific alerts for acarbose have not been prominent, the interconnected nature of pharmaceutical supply chains means that disruptions in one area can have cascading effects, potentially leading to shortages and increased costs.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different geographies to reduce reliance on a single source.

• Invest in Domestic Production: Leverage government incentives like the PLI scheme to enhance local manufacturing capabilities for APIs and KSMs.

• Strengthen Supply Chain Monitoring: Implement robust tracking systems to identify and address potential disruptions proactively.

• Develop Strategic Reserves: Maintain buffer stocks of critical APIs and KSMs to mitigate short-term supply interruptions.

• Enhance Regulatory Compliance: Ensure adherence to international quality standards to facilitate smoother regulatory approvals and market access.

RISK_LEVEL: MEDIUM